Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis

Archive ouverte

Benoit, Jeanne | Muñiz-Castrillo, Sergio | Vogrig, Alberto | Farina, Antonio | Pinto, Anne-Laurie | Picard, Geraldine | Rogemond, Veronique | Guery, Deborah | Alentorn, Agusti | Psimaras, Dimitri | Rheims, Sylvain | Honnorat, Jérôme | Joubert, Bastien

Edité par CCSD ; American Academy of neurology -

International audience. Background and objectives: Previous studies suggested that autoimmune limbic encephalitis with antibodies against contactin-associated protein-like 2 (CASPR2-encephalitis) is clinically heterogeneous and progresses slowly, preventing its early recognition. We aimed to describe the onset and progression of CASPR2-encephalitis and to assess long-term outcomes.Methods: We retrospectively analyzed the medical records of all patients whose CSF tested positive for anti-CASPR2 antibodies in our center between 2006 and 2020. Standardized telephone interviews of all available patients and relatives were conducted, assessing long-term functional independence using the Functional Activity Questionnaire (FAQ) and quality of life using the 36-Item Short-Form Survey (SF36).Results: Forty-eight patients were included (98% males; median age 64 years), and 35 participated in telephone interviews (73%). At onset, 81% had at least 1 neurologic symptom among the following: limbic (54%), peripheral nerve hyperexcitability (PNH; 21%), and/or cerebellar symptoms (17%). Most of the patients (75%) had initially symptoms of only one of these categories. Limbic symptoms at onset included mostly seizures (33%), while memory disturbances were less frequent (10%). PNH signs were mostly neuropathic pain (9/10 patients). Other symptoms seen at onset included asthenia (33%), mood disorders (25%), and insomnia (21%); 19% of patients did not show any limbic, peripheral, or cerebellar symptom at onset but only asthenia (15%), mood disorders (6%), weight loss (8%), dysautonomia (4%), and/or insomnia (2%). The peak of the disease was attained in median 16.7 months after onset. Over the study period (median follow-up, 58.8 months, range 10.6-189.1), 77% of patients developed ≥3 core CASPR2 symptoms and 42% fulfilled the diagnostic criteria for autoimmune limbic encephalitis, although all patients ultimately developed limbic symptoms. At the last visit, most interviewed patients (28/35 patients, 80%; median, 5 years after onset) had recovered functional independence (FAQ <9) while only the vitality subscore of the SF36 was lower than normative data (mean 49.9 vs 58.0, p = 0.0369).Discussion: CASPR2-encephalitis has a progressive course and is highly heterogeneous at the early stage. In men older than 50 years, otherwise unexplained seizures, cerebellar ataxia, and/or neuropathic pain are suggestive of early-stage CASPR2-encephalitis, especially if they coincide with recent asthenia, mood disorders, or insomnia.

Suggestions

Du même auteur

Cerebellar Ataxia With Anti-DNER Antibodies

Archive ouverte | Peter, Elise | CCSD

International audience

Paraneoplastic Neurologic Syndromes Associated With Merkel Cell Carcinoma

Archive ouverte | Ciano-Petersen, Nicolás Lundahl | CCSD

International audience. Background and ObjectivesTo define the clinical and immunologic profile of patients with paraneoplastic neurologic syndromes (PNSs) associated with Merkel cell carcinoma (MCC). MethodsRetrosp...

Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis

Archive ouverte | Ciano-Petersen, Nicolás Lundahl | CCSD

International audience. Background and Objectives Anti-NMDA receptor (NMDAR) encephalitis is defined by the presence of antibodies (Abs) targeting the NMDAR in the CSF. This study aimed to determine the prognostic v...

Chargement des enrichissements...